SGLT2 Inhibitors Linked to Reduced Risk for Serious Renal Events
Data from three countries showed drop in serious renal events with sodium-glucose cotransporter 2 inhibitors
FRIDAY, May 1, 2020 (HealthDay News) -- Use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a reduced risk for serious renal events compared with dipeptidyl peptidase-4 inhibitors, according to a study published online April 29 in The BMJ.
Björn Pasternak, M.D., Ph.D., from the Karolinska Institutet in Sweden, and colleagues examined the correlation between SGLT2 inhibitor use and the risk for serious renal events using data from routine clinical practice in Sweden, Denmark, and Norway. Data were included from a cohort of 29,887 new users of SGLT2 inhibitors and 29,887 propensity score-matched new users of an active comparator, dipeptidyl peptidase-4 inhibitors. Participants were followed for a mean of 1.7 years.
The researchers found that compared with dipeptidyl peptidase-4 inhibitor use, SGLT2 inhibitor use correlated with a reduced risk for serious renal events (2.6 versus 6.2 events per 1,000 person-years; hazard ratio, 0.42). For use of SGLT2 inhibitors versus dipeptidyl peptidase-4 inhibitor use, the hazard ratios were 0.32, 0.41, and 0.77 for the secondary outcomes of renal replacement therapy, hospital admission for renal events, and death from renal causes, respectively.
"Complementing data from clinical trials, this study provides further support for the use of SGLT2 inhibitors in a broad range of patients with type 2 diabetes," the authors write.
Several authors disclosed ties to the pharmaceutical industry.